**Table S2.** The effect of clinical parameters on the achievement of clinical remission (DAS28-ESR < 2.6) at week 52 in the SWITCH group (n = 90).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Unadjusted analysis | | |  | Adjusted analysis\* | | |
|  | OR\*\* [95%CI] | p value | ROC-AUC |  | OR\*\* [95%CI] | p value | ROC-AUC |
| CRP, mg/dL | 1.139 [0.952-1.363] | 0.17 | 0.664 |  | 1.011 [0.803-1.273] | 0.92 | 0.754 |
| IL-6, pg/mL | 0.9994 [0.997-1.002] | 0.68 | 0.478 |  | 0.999 [0.995-1.003] | 0.51 | 0.756 |
| SAA, g/mL | 1.0009 [0.999-1.002] | 0.30 | 0.661 |  | 1.00001 [0.998-1.002] | 0.99 | 0.754 |
| MMP-3, ng/mL | 1.0007 [0.998-1.003] | 0.63 | 0.617 |  | 0.9998 [0.997-1.003] | 0.91 | 0.752 |
| RF, IU/mL | 1.002 [0.99993-1.004] | 0.052 | 0.555 |  | 1.0005 [0.997-1.004] | 0.79 | 0.788 |
| IgG, mg/dL | **1.001 [1.0002-1.003]** | **0.03** | 0.663 |  | **1.002 [1.0004-1.004]** | **0.01** | 0.816 |
| TJC28 | 1.079 [0.989-1.176] | 0.09 | 0.624 |  | 1.041 [0.944-1.148] | 0.43 | 0.755 |
| SJC28 | 1.053 [0.935-1.187] | 0.40 | 0.582 |  | 1.017 [0.879-1.176] | 0.83 | 0.752 |
| ESR, mm/h | **1.022 [1.004-1.040]** | **0.01** | 0.715 |  | 1.015 [0.995-1.036] | 0.15 | 0.790 |
| PGA, mm | 1.019 [0.994-1.044] | 0.12 | 0.640 |  | 1.012 [0.984-1.040] | 0.40 | 0.766 |
| TJC68 | 1.046 [0.990-1.104] | 0.12 | 0.560 |  | 1.037 [0.975-1.102] | 0.26 | 0.768 |
| SJC66 | 1.012 [0.940-1.089] | 0.76 | 0.536 |  | 0.989 [0.905-1.080] | 0.80 | 0.757 |
| EGA, mm | 1.002 [0.974-1.030] | 0.91 | 0.496 |  | 0.992 [0.961-1.024] | 0.62 | 0.751 |
| VAS Pain, mm | 1.011 [0.988-1.035] | 0.35 | 0.572 |  | 1.005 [0.979-1.031] | 0.71 | 0.750 |
| DAS28-ESR | **2.059 [1.180-3.593]** | **0.006** | 0.723 |  | 1.600 [0.857-2.986] | 0.13 | 0.785 |
| CDAI | 1.040 [0.991-1.092] | 0.11 | 0.614 |  | 1.018 [0.963-1.076] | 0.54 | 0.759 |
| SDAI | 1.037 [0.994-1.082] | 0.09 | 0.633 |  | 1.014 [0.966-1.064] | 0.58 | 0.759 |

\*: Adjusted for age, gender, height, body weight, body mass index, disease duration, prednisolone dose, and methotrexate dose. \*\*: Represents predictive value for clinical remission at week 24 by decrease of 1.0 unit of each parameter.